Healthcare Industry News: S.A.
News Release - August 1, 2013
Alexza Announces Management Promotions
MOUNTAIN VIEW, Calif., Aug. 1, 2013 -- (Healthcare Sales & Marketing Network) -- Alexza Pharmaceuticals, Inc. (ALXA) today announced the promotion of Kelly Seither to the newly created position of Vice President, Global Strategic Marketing and New Product Planning, and Tatjana Naranda, PhD, to the newly created position of Vice President, Business Development and Global Alliance Management.Kelly Seither joined Alexza in 2003 as Director, New Product Development and Market ReS.A.ch. She was promoted to Senior Director, New Product Planning and Strategic Marketing in 2007 and to Executive Director, New Product Planning and Strategic Marketing in 2012. Prior to joining Alexza, Ms. Seither was Senior Product Manager at Gilead Sciences from 2002 to 2003 and Senior Product Manager at Aerogen, Inc. from 2001 to 2002. From 1991 to 2001, she had various positions of increasing responsibility at ALZA Corporation in market reS.A.ch, new product planning, saleS.A.d product management. Ms. Seither received a BS in Biological Sciences from California Polytechnic S.A.e University.
Tatjana Naranda, PhD, joined Alexza in 2005 as Director, Business Development. She was promoted to Senior Director, Business Development in 2009 and to Executive Director, Business Development in 2012. Prior to joining Alexza, Dr. Naranda was Chief Operating Officer and Chief Scientific Officer of Receptron, Inc., from 1998 to 2005. Dr. Naranda received a PhD in Molecular Biology from the Autonomous University in Madrid, S.A.n and completed a postdoctoral fellowship in the Department of Biological Chemistry in the School of Medicine at UC Davis. She received an MBA from Golden Gate University, a BSc in Chemistry and an MSc in Biochemistry from the University of Zagreb in Croatia.
About Alexza Pharmaceuticals, Inc.
Alexza Pharmaceuticals is focused on the reS.A.ch, development and commercialization of novel, proprietary products for the acute treatment of central nervous system conditions. Alexza's productS.A.e based on the S.A.cato® system, a hand-held inhaler designed to deliver a drug aerosol to the deep lung, providing rapid systemic delivery and therapeutic onset, in a simple, non-invasive manner.
ADASUVE (S.A.cato loxapine) iS.A.exza's first commercial product, which waS.A.proved by the U.S. Food and Drug Administration in December 2012 and by the European Commission in February 2013. Teva Pharmaceutical USA, Inc. iS.A.exza's commercial partner for ADASUVE in the U.S. Grupo Ferrer Internacional, S.A. iS.A.exza's commercial partner for ADASUVE in Europe, Latin America, RusS.A.and the Commonwealth of Independent S.A.es countries.
For more information about Alexza, the S.A.cato system technology or the Company's development programs, please visit www.alexza.com.
ADASUVE® and S.A.cato® are registered trademarks of Alexza Pharmaceuticals, Inc.
Source: Alexza Pharmaceuticals
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.
RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!